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Isocyanates are highly reactive compounds
used to manufacture polyurethanes. They
account for the greatest number of reported
cases of occupational asthma both in the
United States and in other developed coun-
tries. Hexamethylene diisocyanate (HDI),
one of the most commercially important
isocyanates, is used as a polymerizing agent
in polyurethane spray paint and coating
formulations.
Primary prevention of isocyanate asthma
is problematic because industrial exposures
are widespread and difﬁcult to characterize,
measure, and control. Secondary and tertiary
prevention opportunities are limited because
no simple way has been found to diagnose
isocyanate asthma or identify speciﬁc at-risk
groups. In addition, there is inadequate
knowledge of isocyanate exposure patterns
and the factors that both cause and exacerbate
the disease.
As a result of its reactivity and recog-
nized toxicity, there is great interest in devel-
oping sensitive methods for detection of
human exposure to HDI. Determination of
HDI in the blood, serum, urine, and other
body ﬂuids is difﬁcult because HDI not only
is self-reactive buy may also hydrolyze or
react readily with hydroxyl, sulfhydryl, or
amino groups on proteins. 
Exposure to HDI often occurs in small
shops or garages where workplace monitor-
ing may be inadequate. In addition, mea-
surement only of airborne concentrations is
likely inadequate because animal studies
have indicated that exposure through the
skin can result in respiratory sensitization
(1). Biomonitoring presents an attractive
way to supplement air monitoring. By inte-
grating the burden from all routes of expo-
sure, biomonitoring can estimate the total
internal dose of the agent.
Few biomarkers are available for distin-
guishing exposure to HDI. Previous meth-
ods have used analytic chromatographic
procedures to detect hydrolysis products of
the isocyanate in urine or blood of workers.
Measurement is made of the diamine liber-
ated after acid hydrolysis and extraction of
urine and blood samples (2,3). Levels of the
diamine from methylene diphenyl diiso-
cyanate (MDI) in hydrolyzed plasma ranged
from 0.25 to 226 nmol/L (4). Toluene diiso-
cyanate (TDI) was also detected as the corre-
sponding diamine in hydrolyzed plasma, with
levels of 0.82–45 nmol/L (5). Two studies
attempted biomonitoring for HDI after
exposure of volunteers in test chambers (2,3).
Both studies failed to detect hexamethylene
diamine in hydrolyzed plasma. 
We sought to develop a sensitive and
specific immunoassay for biomonitoring
HDI exposure. Advantages of such an assay
are low cost, readily available equipment
with low maintenance needs, and the ability
to analyze numerous samples simultane-
ously. We report here the development of
immunoassays that have sufﬁcient sensitivity
and specificity to detect workplace HDI
exposures.
Materials and Methods
Synthesis of HDI–protein antigens. We
added 20 µL hexamethylene diisocyanate
(Desmodur HD240, cas # 822-06-0, Bayer
Corp., Pittsburgh, PA; purity 98%) dropwise
to 20 mL of a rapidly stirred 0.5% (w/v)
solution of protein in 0.05 M sodium
borate–KCl buffer (0.05 M H3BO3, 0.05 M
KCl, 0.035 M NaOH, pH 9.4) kept at
37°C. After 4 hr, we added 0.5 mL of
monoethanolamine to stop the reaction. The
solution was filtered, the pH of the super-
natant was adjusted to 4.0, and the mixture
kept at 4°C overnight. The conjugate was
collected by centrifugation, dissolved in 15
mL of 0.1 M (NH4)2CO3 and dialyzed
against 0.05 M NaCl and then water before
lyophilization. Proteins that we reacted with
HDI included keyhole limpet hemocyanin
(KLH; Sigma Co., St. Louis, MO), human
serum albumin (HSA, 97-99% purity; Sigma
Co.), and ovalbumin (OVA; Sigma Co.).
We prepared a series of HDI-HSA conju-
gates by adding increasing amounts of HDI
(1–110 µL) to the 0.5% HSA solution. The
conjugates were isolated as described above. 
Determination of HDI adduction
(TNBS analysis). We estimated the extent of
HDI coupling to protein from the number of
amino groups on the conjugated protein that
remained available for reaction with 2,4,6-
trinitrobenzene sulfonic acid (TNBS; Sigma
Co.) after HDI treatment. We added 50 mL
of freshly prepared 0.03M TNBS to dilu-
tions of 1% solutions of HDI-HSA and HSA
in 0.05 M borate-KCl buffer, pH 9.4 (6).
After 30 min, we measured the absorbance at
420 nm. We calculated the HDI binding as
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Hexamethylene diisocyanate (HDI) is used widely to manufacture polyurethanes for paints and
coatings. It is an irritant and a chemical asthmagen. The U.S. Occupational Safety and Health
Administration time-weighted average permissible exposure limit is 5 ppb and the ceiling limit is
20 ppb. We sought to develop a sensitive and speciﬁc immuno-bioassay to supplement workplace
air monitoring and detect recent HDI exposure. For this, we produced rabbit antiserum to HDI-
adducted keyhole limpet hemocyanin (HDI-KLH). The speciﬁcity of the antiserum was demon-
strated by its reaction with a variety of HDI-conjugated proteins and the absence of reactions
with conjugates of other diisocyanates, namely toluene diisocyanate and diphenyl methylene
diisocyanate. Four immunoassays were developed and compared for their ability to detect decreas-
ing quantities of HDI-adducted human serum albumin (HSA) containing 2 mol HDI adduct per
mol HSA (HDI2-HSA) as determined by matrix-assisted laser desorption time-of-flight
(MALDI-TOF) mass spectrometry. The sensitivities of some of the assays are within the range
(0.82–45 nM) of current analytic methods. A Western analysis procedure has a sensitivity of 600
nM HDI adduct on HSA. ELISA inhibition assay, in which microtiter plates are coated with the
HDI2-HSA antigen, has a sensitivity of 300 nM HDI adduct. An immunoblot assay has a sensi-
tivity of 9 nM HDI adduct. The most sensitive bioassay (1.8 nM HDI adduct) is a three-antibody
sandwich ELISA in which wells of microtiter plates are coated with the IgG fraction of the anti-
HDI-KLH antisera. Compared with analytic methods for HDI biomonitoring, the immunoassays
are faster and less costly and accommodate numerous samples simultaneously. The assays have
the potential to affect industrial biomonitoring programs signiﬁcantly. Key words: biomonitoring,
HDI, immunoassay, occupational asthma. Environ Health Perspect 109:1103–1108 (2001).
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http://ehpnet1.niehs.nih.gov/docs/2001/109p1103-1108lemus/abstract.htmlthe percent of protein amino groups that had
reacted with HDI as follows:
MALDI-TOF MS analysis. We used a
PerSeptive BioSystems Voyager STR
matrix-assisted laser desorption time-of-
flight mass spectrometer (MALDI-TOF
MS) (Framingham, MA) with a high mass
charge (m/z) detector in the linear mode to
collect all of the mass spectra. We dissolved
HDIn-HSA products and the calibrant,
bovine serum albumin (BSA) [molecular
weight (MWave) = 66,431], in 50:50 acetoni-
trile:water and 0.1–0.3% acetic acid. The
matrix used for the MS was 10 mg sinapinic
acid in l mL 50:50 water:acetonitrile with
0.1% triﬂuoracetic acid (TFA) or 0.3% acetic
acid. We mixed 1:1 sample:matrix directly
on the sample plate or in vials with vortexing.
One µL was spotted into a well on the 100-
well, gold-plated stainless steel sample plate
for the analysis. We determined the MS
value of n for the HDIn-HSA adduct by
measuring the average increase in mass of the
product against a HSA standard. We deter-
mined the error in n by a standard deviation
calculation from repeat experiments.
Immunization of rabbits. The immuniza-
tion protocol was similar to that described
previously (7). Two New Zealand white rab-
bits were injected intradermally with 1.8 mg
HDI-KLH emulsiﬁed in 2:3 saline-Freund’s
complete adjuvant (Gibco BRL, Grand
Island, NY). Injections were distributed
among 15 sites along both sides of the back.
After 21 days, rabbits were boosted subcuta-
neously with the same dose of HDI-KLH in
incomplete adjuvant distributed among 5
sites along the nape of the neck. Blood was
drawn 7–10 days following the boost.
Isolation of rabbit IgG. We isolated
immunoglobulin G (IgG) from rabbit antis-
era using a two-step procedure as described by
McKinney and Parkinson (8). We removed
albumin and other non-IgG proteins by pre-
cipitation with caprylic acid. We isolated the
IgG fraction by adding ammonium sulfate to
45% saturation and then centrifuging at
5,000 g for 30 min. The IgG was resus-
pended in a small volume of PBS and then
dialyzed against PBS at 4°C for 16 hr.
Evaluation of antisera using ELISA. We
used ELISA to measure the titer of rabbit
antibodies to HDI-KLH (7). Microtiter
plates (Immulon; Dynex Technologies, Inc.,
Chantilly, VA) were coated by addition of
50 µL of 50 µg/mL HDI-KLH in 0.1 M
carbonate buffer, pH 9.6. We added anti-
serum to wells and made 2-fold dilutions.
After incubation at 37°C for 1 hr, we added
peroxidase-labeled goat antirabbit IgG
(1:3,000, Sigma Co.) and then 2,2-azinobis-
[3-ethylbenzo-thiazoline-6-sulfonic acid]
(ABTS; Sigma) and H2O2. We stopped the
enzymatic reaction by adding 50 µL of 0.05%
SDS. Absorbance was determined at 410 nm.
ELISA inhibition assay. We performed
inhibition assays as described by Jin et al.
(7). Increasing amounts of test inhibitors
dissolved in blotto (PBS containing 0.05%
tween 20, 0.5% nonfat dry milk) were
added to the wells of antigen-coated
microtiter plates before addition of the anti-
HDI-KLH antiserum. After 1 hr at 37°C,
reagents were added as described above to
detect the rabbit IgG. The percent inhibi-
tion was calculated as follows:
Three-antibody sandwich ELISA (TASE).
We coated polyvinyl chloride microtiter
plates (Immulon; Dynex Technologies, Inc.)
with 0.01 mg/mL (50 µL/well) IgG fraction
from rabbit antiserum to the HDI-conju-
gated KLH diluted in 0.1 M carbonate
buffer, pH 9.6. Plates were kept at 37°C for
3 hr and then stored at 4°C. Just before use,
wells were blocked by addition of blotto.
Samples of HDI-adducted HSA containing
dithiothreitol [(DTT) 10 mg/mL; Sigma]
were warmed and then added to the wells.
After 1 hr at 37°C, we added goat anti-whole
human serum (Chemicon International, Inc.,
Temecula, CA) 1:7,000 in blotto with 0.5%
rabbit IgG. We added peroxidase-labeled
rabbit antigoat IgG (Sigma) diluted 1:3,000
in PBS-0.05% tween 20 after 1 hr and incu-
bated plates for an additional hr at 37°C.
Substrate was added as described above and
absorbance determined at 410 nm.
SDS-PAGE of HDI-HSA conjugates.
We dissolved lyophilized aliquots of HDI-
adducted HSA in sample loading buffer
(SLB) composed of 20% of 1.0 M Tris-
HCl, pH 6.8; 40% glycerol; 10% of 10%
SDS; and 0.8% of 0.5% Coomassie G-250
(Bio-Rad, Hercules, CA). We added 2.46
mg/mL DTT to some of the samples just
before use. Samples were heated in a water
bath for 5 min at 95°C and then applied to
a gradient gel (10–20% Tris-Tricine 
SDS gel; Bio-Rad). Electrophoresis was
performed at constant voltage (100 V,
approximately 65 mA). 
Western analysis. We placed polyacry-
lamide gels in transfer buffer (pH 8.3) com-
posed of 192 mM glycine, 25 mM Tris-base,
0.037% SDS, and 20% methanol for 1 hr.
We transferred proteins from the gels to
nitrocellulose membranes (0.45 µm, Bio-
Rad) using a Mini Trans-Blot Cell (Bio-Rad)
operated at constant voltage (100 V) for 1.5
hr at 4°C. Membranes were washed 3 times
with Tris-buffered saline (TBS, 20mM Tris,
500 mM NaCl, pH 7.5) and blocked
overnight at 4°C by immersion in a solution
of TBS containing 5% nonfat dry milk (Bio-
Rad) with gentle agitation. We added anti-
serum to HDI-adducted KLH diluted
1:1,000 in TBS containing 0.5% dry nonfat
milk and kept the membranes at 10°C for 24
hr. We detected bound antibodies using
biotinylated goat antirabbit IgG [Ampliﬁed
Alkaline Phosphatase Goat Anti-Rabbit
Immuno-Blot Assay Kit (AAPGAR) Bio-Rad]
diluted 1:3,000 in tween-TBS (0.05% tween
20), pH 7.5, and incubation continued for 2
hr at ambient temperature. After washing,
streptavidin-biotinylated alkaline phosphatase
complex was added, and the membrane was
kept at ambient temperature for 2 hr. We
added substrate (5-bromo-4-chloro-3-indole
phosphate/nitroblue tetrazolium). We
stopped the reaction after 2.5 min by rinsing
the membrane in distilled water. 
Dot blot assay. Samples of HDI conju-
gate (0.002–4 µg) containing 10 mg/mL
DTT were heated in a water bath for 5 min
at 95°C and then blotted onto nitrocellulose
membranes (0.45 µm; Bio-Rad). We used
rabbit IgG isolated from the antiserum
raised to HDI-adducted KLH to detect HDI
adducts. Spots were visualized as described
above for the Western analysis.
Calculation of immunoassay sensitivity. 
The sensitivity of each immunoassay was cal-
culated as follows:
Results
Specificity of the antiserum to HDI-
adducted KLH. Sera from the two rabbits
were mixed and evaluated for reactivity with
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Figure 1. Specificity of the antiserum to HDI-
adducted KLH. Each antigen was used to coat a
microtiter plate. Bound antibody was detected
using 1:3,000 peroxidase-labeled goat antirabbit
IgG. The reactivity of the antiserum with all HDI-
adducted antigens, but not with HSA or OVA, indi-
cated an anti-HDI hapten titer of 50,000. 
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OVAHDI-adducted proteins. Using ELISA, we
noted reactions with each of the proteins
that we had reacted with HDI (Figure 1).
Reaction was also detected with KLH, but
not with OVA or HSA. The near identity of
the titers obtained with HDI-adducted
OVA and HDI-adducted HSA indicates
that the antiserum has an “anti-HDI” hap-
ten titer of approximately 50,000. 
Characterization of HDI-protein
conjugates. We anticipated that conjugates
formed in vivo following occupational expo-
sure would contain a small number of
adducts. Accordingly, we sought to prepare
a conjugate containing only one or two
HDI adducts that could be used to develop
the immunoassays. We synthesized conju-
gated proteins under conditions of physio-
logic pH and temperature, employing molar
ratios of HDI:HSA that ranged from 0.8
to 91.3. 
We analyzed the extent of adduction of
the conjugate series by three methods. A
comparison of the methods is presented in
Table 1. Using the TNBS method, we
found that adduction was a linear function
of the initial HDI concentration. However,
some of the conjugates that tested negative
in the TNBS assay gave a positive response
with the rabbit anti-HDI adduct antiserum
(conjugates B and C, Table 1). Because the
TNBS reagent assesses primarily chemical
adduction with amino groups (9), we per-
formed additional analyses using mass spec-
trometry. We synthesized conjugate A using
a molar ratio of HDI:HSA of 45.6:1.
MALDI-TOF-MS detected an average of
20.6 mol HDI adduct per mol HSA,
whereas TNBS indicated 12 mol adduct per
mol protein (Table 1). This difference may
be caused by the reaction of HDI with
nucleophilic groups other than amines. The
TNBS method could not detect adduction
on either conjugate B or C. In the immuno-
logically based Western blot assay, conjugate
B gave a moderately strong response and
conjugate C showed a weak response. 
The MALDI mass spectra in Figure 2
show typical data collected for the HSA con-
trol in Figure 2A and for two different con-
jugates in Figures 2B and 2C. Figures 2B
and 2C illustrate conjugates that tested nega-
tive with TNBS but positive in the Western
blot immunoassay (Table 1). The standard
deviation in the MW determination of the
calibrant, BSA (MWave = 66,431 amu), from
11 runs was ± 44 amu (± 2σ). Although
BSA is not recommended as a calibrant for
MALDI-TOF-MS because it is typically not
pure and can produce a systematic error, the
determination of the number of HDI mole-
cules adducted was calculated by mass differ-
ence. The average MWave of the HSA
control determined from six runs by
MALDI-TOF-MS was 66,653 ± 126 amu.
One mass spectrum of the HSA control is
shown in Figure 2A with m/z 66,662 for the
[M+H]+ ion. This MW is approximately
200 amu higher than expected. We suspect
that the HSA may be complexed with fatty
acids or modified by other plasma mole-
cules. One of six analyses of conjugate B is
shown in Figure 2B labeled with m/z
66,985 for the [M+H]+ ion. The six mea-
surements produced a MWave of 66,980 ±
70 amu for conjugate B, indicating an aver-
age of two HDI adducts per molecule of
HSA. Figure 2C shows one of six trials used
to measure the MW of conjugate C found
here with m/z 66,670 for the [M+H]+ ion.
The six measurements of conjugate C pro-
duced a MW of 66,664 ± 70 amu, indicat-
ing an average of 0.1 HDI adduct per
molecule of HSA. The error in this latter set
of experiments is greater than the deter-
mined number of HDI adduct molecules.
Reactivity of the antiserum to HDI-
adducted KLH. We used the Western blot
procedure to evaluate the reactivity of the
antiserum with diverse chemical haptens.
HSA was reacted with HDI, with other
diisocyanates such as TDI and MDI, and
with the industrial chemicals formaldehyde
and cyanuric chloride. Each of these HSA-
conjugates was evaluated with the TNBS
reagent and found to contain a minimum of
17 haptenic moieties per molecule HSA.
Each conjugate was subjected to gel elec-
trophoresis, transferred to a nitrocellulose
membrane, and probed with the antiserum
to determine antibody cross-reactivity. Of
the antigens tested, only HDI2-HSA reacted
with the antiserum (Figure 3, lane 6). Two
bands were detected, a broad band at 69
kDa and a narrower band at 128 kDa. Both
bands were identiﬁed as HSA by amino acid
sequencing. 
The lack of reaction of the antiserum
with HSA (lane 1) and with other chemi-
cally adducted conjugates (lanes 2–5), and
the positive response with HDI2-HSA (lane
6) highlights not only the specificity of the
antiserum for HDI hapten, but also its sensi-
tivity by its ability to react with the hapten
when present to the extent of 0.2% of the
mass of the conjugate. 
Immunoassays for HDI adduct. We
developed four immunoassays for biomoni-
toring HDI-adducted proteins present in
ﬂuids. We tested each to determine its sensi-
tivity in detecting HDI adducts on the
HDI2-HSA conjugate. An immunoblot
method employed nitrocellulose, to which
was applied HDI2-HSA (heated in the pres-
ence of DTT). We visualized adducts using
1:1,000 rabbit anti-HDI–conjugated KLH
antiserum, followed by goat antirabbit IgG.
As indicated in Figure 4, the antiserum
detected from 0.031 to 4.0 µg adducted pro-
tein. At concentrations < 0.031 µg, staining
Articles • Immunoassays to detect HDI
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Table 1. Characterization of HSA adduction by HDI using spectroscopic and immunologic procedures.
Molar ratio of  Number of HDI adducts bound
reactants to HSA as determined by Western blot
Conjugate HDI/HSA MALDI-TOF-MS TNBS immunoassay
A 45.6 20.6 ± 0.9a 12a ++++b
B 2.5 2.0 ± 0.9 ND +++
C 0.8 0.1 ± 0.9 ND +
Abbreviations: ND, not detected; TNBS, trinitrobenzenesulfonic acid.
aOnly portion soluble at pH 4 was analyzed. bNumber of plus signs (+) denotes relative stain intensity, scale + to ++++. 
Figure 2. MALDI-TOF mass spectra. Typical mass spectrum of (A) human serum albumin control, (B) HDI2-HSA product, and (C) HDI0.1-HSA product. Note also the
assignments of the doubly charged ions [M + 2H]+2 and proton-bound dimer ions [2M + H]+ in the spectra.
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m/z m/zwas not distinguishable from that obtained
with HSA. Using the equation provided in
“Methods,” the sensitivity of this method for
detecting HDI adducted to protein is (0.03
× 2)/(66,500 × 100) = 9.3 nM.
We evaluated the Western blot method
for its sensitivity in detecting the adduct. We
applied quantities of HDI2-HSA conjugate
(0.2–10 µg) to gradient gels. Two bands
were present in the HSA starting material
(Figure 5A), and we detected HDI adducts
on both bands (Figure 5B). The antiserum
routinely detected 0.2 µg of HDI-adducted
HSA (lane 12), yielding a sensitivity of 600
nM HDI hapten.
We developed an ELISA inhibition
method in which HDI2-HSA (heated under
reducing conditions) was used to coat the
microtiter plates. Addition of increasing
amounts of this conjugate to the wells just
before addition of the antiserum yielded a
standard inhibition curve (Figure 6). The
smallest quantity of inhibitor that could be
detected was 0.25 µg (7.6 pmol HDI hap-
ten). The method can detect 300 nM HDI
conjugate. 
The ﬁnal immunoassay developed was a
three-antibody sandwich ELISA (TASE). In
this procedure we used IgG (0.01 mg/mL)
purified from the rabbit anti-HDI conju-
gated KLH antiserum to coat the plates. We
added HDI conjugate to the IgG-coated
wells. We detected bound HDI hapten using
goat antihuman serum followed by peroxi-
dase-labeled antigoat IgG. Detection of
HDI2-HSA is shown in Figure 7. No bind-
ing was obtained with HSA. This assay has a
detection limit of 0.003 µg of HDI-
adducted protein, yielding a sensitivity of
1.8 nM HDI hapten.
Discussion
1,6-Hexamethylene diisocyanate, also referred
to as 1,6-diisocyanatohexane, is a widely used
industrial chemical. Its use, coupled with its
recognized acute toxicity and chronic conse-
quences, requires careful monitoring of work-
place environments. Rapid identification of
exposures is essential to prevent adverse
health effects. For isocyanates, monitoring
the workplace may not be adequate because
many exposures are intermittent and occur in
small shops or garages where routine air
monitors are not installed. Because biomoni-
toring can integrate exposures that result
from diverse routes, such as dermal and
inhalation, it presents an attractive supple-
ment to detect workplace exposures.
Reliable data regarding human exposure
to diisocyanates are lacking. Monitoring air-
borne TDI concentration has not prevented
adverse health effects in exposed workers
(10). Biomonitoring may be a valuable sup-
plement. For chemicals such as TDI, which
function as haptens, measurement of the
immune response, such as the amount of
circulating antibody reactive with TDI-
conjugated HSA, has been proposed as a
means to biomonitor exposure (11).
Animal studies have found a direct depen-
dence of the immunologic response on the
airborne isocyanate concentration (12). This
approach has limitations, however, in that
antibodies have not been detected in all
exposed individuals (13), and the effect on
antibody production of repeated exposures
after variable periods of time remains to be
clarified. Detection of bound diisocyanate,
as we describe here, offers advantages when
compared with biomonitoring for the
immunologic response resulting from diiso-
cyanate exposure, because the former mea-
sures only recent exposure (within the past
several weeks) whereas the immune response
may represent exposure occurring over previ-
ous months (11). 
Of foremost importance in designing a
procedure for biomonitoring is adequate
sensitivity of the assay. Immunoassays are
known to have high sensitivity with antigen
detection limits typically in the femtomole
range (14). They have been used to study
the mutagenic and carcinogenic potential of
diverse electrophilic chemicals and their
metabolites by assessing DNA adducts (15).
Protein adducts, most frequently employing
hemoglobin and serum albumin, have been
used to gauge exposure to benzene, aromatic
amines, and other xenobiotics (16).
Chromatographic methods are currently
in use for biomonitoring diisocyanates. TDI
and MDI have been detected as the corre-
sponding diamines in acid hydrolyzed urine
and blood specimens (3,5). A relationship
has been shown between airborne isocyanate
levels and concentrations of diamines in
hydrolyzed urine from TDI-exposed work-
ers. Using HPLC and GC-MS, detection
limits in the biologic matrix of 10 nM have
been reported (17).
We report development of four types of
immunoassay for detecting HDI adduct. All
derive their specificity from the same poly-
clonal antiserum. By design, the isocyanate
hapten is quantified irrespective of the bio-
molecule to which it is adducted. This is
important because the in vivo bioreactant(s)
is unknown. In vitro studies have shown that
the electrophilic N=C=O moiety reacts
rapidly with a variety of nucleophilic groups
on amino acids such as terminal amino
groups and ε-amino of lysine, thiol in cys-
teine, phenolic hydroxyl group in tyrosine,
Articles • Lemus et al.
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Figure 3. Western blot analysis of antibody cross-
reactivity. H/P, hapten/protein ratio. Ten micro-
grams of protein was loaded into each lane. 
Figure 4. Immunoblot assay for detection of HDI
hapten. 
Figure 5. Western blot assay for detection of HDI adducts. (A) Coomassie Blue stain of protein bands.
Both the 69 kDa and the 128 kDa bands were identified as HSA. (B) Detection of HDI adducts. Protein
added to lane 1: 10 mg HSA; to lanes 2–12 HDI-adducted HSA in the following amounts: 10 µg (lane 2), 7 µg
(lane 3), 5 mg (lane 4), 3 µg (lane 5), 2 µg (lane 6), 1.0 mg (lane 7), 0.9 µg (lane 8), 0.8 µg (lane 9), 0.5 µg (lane
10), 0.3 µg (lane 11), and 0.2 µg (lane 12).
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Band the imidazole group in histidine (18,19).
At pH 7.4 in 50% dioxane, the HDI adduct
with N-acetyl cysteine was unstable. Under
physiologic conditions, the most likely HDI
adducts with proteins are N-terminal amino
acids and lysine residues (18). 
The specificity of the rabbit antiserum
was of prime importance in developing the
bioassays. We examined its cross-reactivity
by testing antibody recognition of adducts
formed from other diisocyanates (TDI and
MDI), as well as adducts of electrophiles
such as formaldehyde and cyanuric chloride.
The lack of antibody reaction with any of
these hapten-HSA conjugates indicates that
antibody speciﬁcity is not directed solely to
the urea group. The specificity observed in
the current study, together with previous
findings (20), indicates that hexyl moieties
comprise a portion of the epitope. The true
epitopes in diisocyanate-conjugated proteins
remain unknown, and several different epi-
topes may exist. This issue is the subject of
ongoing studies.
Two of the immunoassays (ELISA inhi-
bition and TASE) detect HDI hapten bound
to small molecules (acid soluble amino acids
or peptides) as well as to proteins. Recent
studies from our laboratory and elsewhere
have indicated a favorable, rapid, and
reversible reaction of TDI with the sulfhydryl
moiety of glutathione. We detected rapid
transcarbamoylation upon addition of a
sulfhydryl-containing protein to the bis(S-
glutathionyl) adducts of TDI and HDI
(21,22). Such adducts, if present in biologic
ﬂuids, would be detected by the ELISA inhi-
bition assay and TASE described here. 
Workers exposed to airborne TDI had
TDI in plasma covalently bound with albu-
min (23). For this reason, we used the albu-
min conjugate of HDI to develop the
bioassays. To parallel the environmental sit-
uation further, we synthesized a conjugate
that contained a minimum number of HDI
adducts. HDI2-HSA was used to develop
each of the assays. 
We found it necessary to pretreat the
HDI conjugates with dithiothreitol before
their use. In the immunoblot procedure, the
rabbit antiserum to HDI-adducted KLH did
not detect conjugates with fewer than four
HDI haptenic moieties unless the conjugates
were heated under reducing conditions (data
not shown). The same effect was reported by
Jin et al.(7). The reduction of disulfide
bonds by DTT likely provides greater acces-
sibility of the antibodies to HDI-adducted
regions of the protein. 
We compared the four immunoassays
for sensitivity and other attributes important
in biomonitoring procedures. As indicated
in Table 2, the assays differ in sensitivity by
approximately two orders of magnitude. As
currently performed, ELISA inhibition and
TASE have adequate sensitivity to detect
workplace isocyanate concentrations.
Moreover, the immobilized immunoglobu-
lins in the latter assay can be an afﬁnity sur-
face to concentrate HDI-adducted molecules
from biologic fluids, thereby significantly
increasing the sensitivity of the procedure. 
The assays described here possess other
advantages when compared with current
chromatographic methods. The chromato-
graphic determinations rely on acid hydroly-
sis of biologic ﬂuids to release the diamine.
Strong acid is needed, and the amount of
amine detected depends on the hydrolysis
conditions used. By contrast, the immunoas-
says require only mild heating of the samples
under denaturing conditions. The treated
plasma is added directly to the microtiter
wells (or nitrocellulose membrane) without
need for acid hydrolysis, extraction, or
derivatization of product. 
Because none of the four immunoassays
has been optimized, modiﬁcation of various
parameters may further enhance the sensitiv-
ity of each of them. Future work in our labo-
ratory will directly compare findings from
the analytic chromatographic methods with
results from our immunobioassays to assess
the applicability of these immunoassays.
Thereafter, protocols applicable for sam-
pling, collecting, and testing in the occupa-
tional and environmental setting will be
developed.
In summary, we have developed four
immunoassays for use in biomonitoring of
HDI exposure. The sensitivity of the assays
range from 1.8 to 600 nM HDI adduct. By
comparison with current analytic methods of
biomonitoring for this diisocyanate, the
immunoassays are faster, easier, and less costly
and require less technical expertise. Most
important, they can be employed for routine
screening for total HDI exposure and are
applicable to industrial surveillance programs
to prevent adverse biologic consequences. 
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